Current pharmacological treatments for Tourette Syndrome (TS), such as antipsychotic agents and α-2 agonists, are moderately effective in the treatment of tics, but have substantial side effects that limit their use. N-acetylcysteine (NAC) modulates glutamatergic systems, and has been used safely as an antioxidant agent with minimal side effects for decades. NAC has been increasingly studied for the treatment of other obsessive-compulsive spectrum disorders. We aim to examine the efficacy of NAC for the treatment of pediatric TS in a double-blind, placebo-controlled, add-on study.
Methods:
Thirty-one children and adolescents 8–17 years of age with TS were randomly assigned to receive NAC or matching placebo for 12 weeks. Our primary outcome was change in severity of tics as measured by the Yale Global Tic Severity Scale (YGTSS), Total tic score. Secondary measures assessed comorbid obsessive-compulsive disorder (OCD), depression, anxiety, and attention-deficit/hyperactivity disorder (ADHD). Linear mixed models in SAS were used to examine differences between NAC and placebo.
Results:
Of 31 randomized subjects, 14 were assigned to placebo (two females; 11.5 + 2.8 years) and 17 to active NAC (five females; 12.4 + 1.4 years) treatment. No significant difference between NAC and placebo was found in reducing tic severity or any secondary outcomes.
Conclusions:
We found no evidence for efficacy of NAC in treating tic symptoms. Our findings stand in contrast to studies suggesting benefits of NAC in the treatment of other obsessive-compulsive spectrum disorders in adults, including OCD and trichotillomania, but are similar to a recent placebo-controlled trial of pediatric trichotillomania that found no benefit of NAC.
Get full access to this article
View all access options for this article.
References
1.
AdamczykA, GauseCD, SattlerR, VidenskyS, RothsteinJD, SingerH, WangT: Genetic and functional studies of a missense variant in a glutamate transporter, SLC1A3, in Tourette syndrome. Psychiatr Genet, 21:90–97, 2011.
2.
AdlerLA, SpencerT, FaraoneSV, KesslerRC, HowesMJ, BiedermanJ, SecnikK: Validity of pilot Adult ADHD Self-Report Scale (ASRS) to rate adult ADHD symptoms. Ann Clin Psychiatry, 18:145–148, 2006.
AlvarengaP, MastrorosaR, RosárioM: Obsessive-compulsive disorder in children and adolescents. In: The IACAPAP Textbook of Child and Adolescent Mental Health. Edited by ReyJM. Paris: IACAPAP; 2012.
5.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
6.
AndersonGM, PollakES, ChatterjeeD, LeckmanJF, RiddleMA, CohenDJ: Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome. Adv Neurol, 58:123–133, 1992.
BlochMH, PanzaKE, GrantJE, PittengerC, LeckmanJF: N-acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry, 52:231–240, 2013.
12.
BlochMH, PanzaKE, Landeros–WeisenbergerA, LeckmanJF: Meta-analysis: Treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry, 48:884–893, 2009.
13.
BlochMH, PetersonBS, ScahillL, OtkaJ, KatsovichL, ZhangH, LeckmanJF: Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Arch Pediatr Adolesc Med, 160:65–69, 2006.
CotgreaveIA: N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol, 38:205–227, 1997.
16.
CraneJ, FagernessJ, OsieckiL, GunnellB, StewartSE, PaulsDL, ScharfJM, Tourette Syndrome International Consortium for Genetics (TSAICG): Family-based genetic association study of DLGAP3 in Tourette Syndrome. Am J Med Genet B Neuropsychiatr Genet, 156B:108–114, 2011.
17.
DasP, TaniousM, FritzK, DoddS, DeanOM, BerkM, MalhiGS: Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo. Aust N Z J Psychiatry, 47:347–354, 2013.
18.
De RosaSC, ZaretskyMD, DubsJG, RoedererM, AndersonM, GreenA, MitraD, WatanabeN, NakamuraH, TjioeI, DeresinskiSC, MooreWA, ElaSW, ParksD, HerzenbergLA, HerzenbergLA: N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clinical Invest, 30:915–929, 2000.
19.
DeVitoTJ, DrostDJ, PavloskyW, NeufeldRW, RajakumarN, McKinlayBD, WilliamsonPC, NicolsonR: Brain magnetic resonance spectroscopy in Tourette's disorder. J Am Acad Child Adolesc Psychiatry, 44:1301–1308, 2005.
20.
DionY, AnnableL, SandorP, ChouinardG: Risperidone in the treatment of Tourette syndrome: A double-blind, placebo-controlled trial. J Clin Psychopharmacol, 22:31–39, 2002.
21.
FerraoYA, MiguelE, SteinDJ: Tourette's syndrome, trichotillomania, and obsessive-compulsive disorder: How closely are they related?. Psychiatry Res, 170:32–42, 2009.
22.
GoodmanWK, PriceLH, RasmussenSA, MazureC, FleischmannRL, HillCL, HeningerGR, CharneyDS: The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry, 46:1006–1011, 1989.
23.
GrantJE, OdlaugBL, KimSW: N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry, 66:756–763, 2009.
24.
GrayKM, CarpenterMJ, BakerNL, DeSantisSM, KrywayE, HartwellKJ, McRae-ClarkAL, BradyKT: A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry, 169:805–812, 2012.
25.
HardanAY, FungLK, LiboveRA, ObukhanychTV, NairS, HerzenbergLA, FrazierTW, TirouvanziamR: A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry, 71:956–961, 2012.
26.
KovacsM. The Children's Depression, Inventory (CDI). Psychopharmacol Bull, 21:995–998, 1985.
27.
KupchikYM, MoussawiK, TangXC, WangX, KalivasBC, KolokithasR, OgburnKB, KalivasPW: The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine. Biol Psychiatry, 71:978–986, 2012.
28.
LeckmanJ, BlochM, SukhodolskyD, ScahillL, KingR: Phenomenology of tics and sensory urges: the self under siege. In: Tourette Syndrome. Edited by MartinoD.New York: Oxford Unity Press; 2013; pp. 3–25.
29.
LeckmanJF, RiddleMA, HardinMT, OrtSI, SwartzKL, StevensonJ, CohenDJ: The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry, 28:566–573, 1989.
30.
MarchJS, ParkerJD, SullivanK, StallingsP, ConnersCK: The Multidimensional Anxiety Scale for Children (MASC): Factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry, 36:554–565, 1997.
PiacentiniJ, WoodsDW, ScahillL, WilhelmS, PetersonAL, ChangS, GinsburgGS, DeckersbachT, DziuraJ, Levi-PearlS, WalkupJT: Behavior therapy for children with Tourette disorder: A randomized controlled trial. JAMA, 303:1929–1937, 2010.
37.
PlessenKJ, Wentzel–LarsenT, HugdahlK, FeineigleP, KleinJ, StaibLH, LeckmanJF, BansalR, PetersonBS: Altered interhemispheric connectivity in individuals with Tourette's disorder. Am J Psychiatry, 161:2028–2037, 2004.
38.
RobertsonMM, SternJS: Gilles de la Tourette syndrome: Symptomatic treatment based on evidence. Eur Child Adolesc Psychiatry, 9Suppl 1:I60–75, 2000.
39.
RoessnerV, RothenbergerA: Pharmacological treatment of tics. In: eds. Tourette Syndrome. Edited by MartinoD.New York: Oxford Unity Press; 2013; pp. 454–452.
40.
RoessnerV, RothenbergerA, RickardsH, HoekstraPJ: European clinical guidelines for Tourette syndrome and other tic disorders. Eur Child Adolesc Psychiatry, 20:153–154, 2011.
41.
ScahillL, ChappellPB, KimYS, SchultzRT, KatsovichL, ShepherdE, ArnstenAF, CohenDJ, LeckmanJF: A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry, 158:1067–1074, 2001.
42.
ScahillL, LeckmanJF, SchultzRT, KatsovichL, PetersonBS: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology, 60:1130–1135, 2003.
43.
ShapiroM, SilvaSG, ComptonS, ChrismanA, DeVeaugh-GeissJ, Breland-NobleA, KondoD, KirchnerJ, MarchJS: The child and adolescent psychiatry trials network (CAPTN): Infrastructure development and lessons learned. Child Adolesc Psychiatry Ment Health, 3:12, 2009.
44.
SommerIE, van WestrhenenR, BegemannMJ, de WitteLD, LeuchtS, KahnRS: Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull, 40:181–191, 2014.
45.
van VelzenLS, VriendC, de WitSJ, van den HeuvelOA: Response inhibition and interference control in obsessive-compulsive spectrum disorders. Front Hum Neurosci, 8:419, 2014.
46.
WeismanH, QureshiIA, LeckmanJF, ScahillL, BlochMH: Systematic review: Pharmacological treatment of tic disorders––efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev, 37:1162–1171, 2013.
47.
WetterneckCT, TengEJ, StanleyMA: Current issues in the treatment of OC-spectrum conditions. Bull Menninger Clin, 74:141–166, 2010.
48.
WoodsDW, PiacentiniJ, HimleMB, ChangS: Premonitory urge for tics scale (PUTS): Initial psychometric results and examination of the premonitory urge phenomenon in youths with tic disorders. J Dev Behav Pediatr, 26:397–403, 2005.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
